# Sichuan Huiyu Pharmaceutical

Source: https://onco.cc/companies/sichuan-huiyu-pharmaceutical/  
OnCo record `sichuan-huiyu-pharmaceutical` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sichuan Huiyu Pharmaceutical is a China-based pharmaceutical company that leads 5 cancer trials in OnCo, testing the in-house candidates HY0001a, HY05350, HY07121, HYP-6589 and HYP-2090 in advanced solid tumours.

## Summary

Sichuan Huiyu Pharmaceutical is a research-driven pharmaceutical company that develops, manufactures and sells anti-tumour and injectable medicines for global markets, with a growing pipeline of in-house innovative drugs and a UK subsidiary, Seacross Pharma. It is listed on the Shanghai Stock Exchange STAR Market. On ClinicalTrials.gov it is the lead sponsor of 5 trials recorded in OnCo: NCT07069062 (phase 1/2, A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced So...), NCT07083323 (phase 1/2, A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors), NCT06712680 (phase 1/2, A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Com...), NCT06639256 (phase 1/2, Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With A...) and NCT06243354 (phase 1/2, Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS M...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Huiyu Pharma; 四川汇宇制药
- Tags: ctgov-sponsor
- HQ: Neijiang, Sichuan
- Type: pharma
- Website: https://www.huiyupharma.com/
- Ticker: SSE:688553

## Sources

- Official website: https://www.huiyupharma.com/
- ClinicalTrials.gov: trials led by Sichuan Huiyu Pharmaceutical: https://clinicaltrials.gov/search?lead=Sichuan%20Huiyu%20Pharmaceutical%20Co.%2C%20Ltd

## Connected records

- trials: [A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors](https://onco.cc/trials/nct07069062/), [A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors](https://onco.cc/trials/nct07083323/), [A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes](https://onco.cc/trials/nct06712680/), [Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06639256/), [Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation](https://onco.cc/trials/nct06243354/)

---
JSON: https://onco.cc/api/v1/entities/sichuan-huiyu-pharmaceutical.json